Administrative/Clinical Trials Core

行政/临床试验核心

基本信息

批准号：
7680151
负责人：
Kirby I. Bland
金额：
$ 28.12万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/7680151
关键词：
90Y-DOTA-Biotin Accounting Achievement Activation Date Address Adenocarcinoma Adenovirus Vector Adenoviruses Adjuvant Administrative Personnel Administrator Advertisements Advisory Committees Advocacy Advocate African African American Age Alabama Amendment American American Association of Cancer Research American Cancer Society American College of Surgeons American College of Surgeons Oncology Group American Society of Clinical Oncology Animal Experiments Animal Model Antibodies Apoptosis Appendix Applications Grants Appointment Area Arts Aspirate substance Atlases Atypia Avastin Award Awareness Back Baltimore Basic Science Behavioral Research Belief Benchmarking Benign Bibliography Biochemistry Biodistribution Bioinformatics Biological Biological Assay Biological Markers Biology Biomedical Research Biometry Blood Blood specimen Bone Marrow Neoplasms Boston Brain Breast Breast Cancer Cell Breast Cancer Detection Breast Cancer Prevention Breast Carcinoma Breast Diseases Breast Feeding Budgets Businesses Cancer Center Cancer Center Support Grant Cancer Patient Cancer Survivor Cancer Therapy Evaluation Program Cancer and Leukemia Group B Cancer cell line Capecitabine/Paclitaxel Carboplatin Caring Categories Cell Cycle Checkpoint Cell surface Cells Cellular Morphology Cellular biology Center Core Grants Centers of Research Excellence Cetuximab Chairperson Characteristics Chemoprevention Chemopreventive Agent Chemotherapy-Oncologic Procedure Child Chimeric Proteins Cities Classification Clinic Clinical Clinical Chemoprevention Clinical Data Clinical Investigator Clinical Protocols Clinical Research Clinical Trials Clinical trial protocol document Closure Collaborations Collection Combined Modality Therapy Commit Communication Communities Community Health Complex Comprehension Comprehensive Cancer Center Computer software Computers Conduct Clinical Trials Confidentiality of Patient Information Conflict of Interest Consent Forms Consultations Consumer Advocates in Research and Related Activities Controlled Study Core Facility Counseling County Critiques Cyclic AMP Cyclophosphamide Cytology Cytotoxic T-Lymphocytes DOTA-biotin Daily Dana-Farber Cancer Institute Data Data Analyses Data Collection Databases Decision Making Dependovirus Depth Development Devices Diagnosis Direct Costs Discipline Disease Disease Progression Disease remission Disease-Free Survival Disorder by Site Doctor of Medicine Doctor of Philosophy Dose Dose-Limiting Doxorubicin Drug Kinetics Drug resistance Ductal EGF gene ERBB2 gene Eastern Cooperative Oncology Group Education Educational Curriculum Educational Materials Educational workshop Eligibility Determination Emotional Stress Employment Enrollment Ensure Environment Epidemiology Epidermal Growth Factor Receptor Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Epithelial Cells Epithelium Equilibrium Equipment Erlotinib Estradiol Estrogen Antagonists Estrogen receptor positive Estrogens Evaluation Excision Expenditure Faculty Family Feedback Fellowship Florida Foundations Frequencies Friends Functional disorder Funding Funding Agency Future G-Protein-Coupled Receptors GTP-Binding Proteins Gastrointestinal tract structure Gender Gene Expression General Practices Generations Genes Genetic Genistein Goals Government Grant Granulocyte-Macrophage Colony-Stimulating Factor Guanosine Monophosphate Guidelines Head Health Health Insurance Portability and Accountability Act Health Personnel Health Services Hematology Heparin Binding High Risk Woman Histologic Hormonal Hormonal Change Hormone Receptor Hormones Hour Howard Temin Award Human Human Biology Human Resources Image Imaging Techniques Immune Immune response Immunology Immunotherapy In Situ Incidence Individual Industry Industry Collaborators Infant Information Systems Informed Consent Institutes Institution Intellectual Property Internal Medicine Intervention Intervention Trial Interview Intestinal Cancer Intravenous Invasive Investigation Iowa Irrigation Journals K-Series Research Career Programs Kansas Knowledge Label Laboratories Laboratory Research Language Lasers Leadership Left Letrozole Letters Life Link Liquid substance Lobular Carcinoma Local Area Networks Localized London Los Angeles Louisiana Magnetic Resonance Imaging Mails Malignant - descriptor Malignant Neoplasms Malignant neoplasm of pancreas Mammary Gland Parenchyma Mammography Management Audit Manuscripts Marrow Maximum Tolerated Dose Measurement Measures Mediating Medical Medical Oncologist Medical Oncology Medical center Medicine Memorial Sloan-Kettering Cancer Center Menopause Mentors Mentorship Meta-Analysis Metabolic Methodology Methods Methylation Michigan Microdissection Minority Mission Molecular Molecular Genetics Molecular Profiling Molecular and Cellular Biology Monitor Monitoring Clinical Trials Monoclonal Antibodies Monoclonal Antibody CC49 Mus NCI Director&apos s Consumer Liaison Group Names National Cancer Advisory Board National Cancer Institute National Surgical Adjuvant Breast and Bowel Project Nature Needles Neoadjuvant Therapy Neoplasm Metastasis Network-based New York Newly Diagnosed Nipples Normal tissue morphology North Carolina Notification Nuclear Numbers Nurses Nursing Research Nutritional Oncogenes Online Systems Operative Surgical Procedures Outcome Ovary PCNA gene Paclitaxel Pancreas Participant Pathologic Pathology Pathway interactions Patient Care Patient Education Patient Recruitments Patient advocacy Patient currently pregnant Patients Pattern Peer Review Peer Review Grants Performance Personal Computers Personal Satisfaction Personnel Recruitments Persons Pharmacists Pharmacologic Substance Pharmacy facility Phase Phase I Clinical Trials Phase I/II Trial Phase II Clinical Trials Phase III Clinical Trials Phenotype Philadelphia Physical Examination Physician Executives Physicians Physiology Plasma Plasmid Cloning Vector Pliability Policies Polynucleotide Vaccines Population Populations at Risk Positioning Attribute Positron-Emission Tomography Postmenopause Preparation Prevention Prevention Research Prevention intervention Principal Investigator Prior Chemotherapy Problem Solving Procedures Process Production Productivity Professional counselor Program Description Program Development Progress Reports Proliferative Index Protein Overexpression Protein Subunits Proteins Proto-Oncogene Proteins c-akt Protocols documentation Public Health Schools Publications Publishing Purpose Pyrroloiminoquinones Qualifying Quality Control Radiation Radioactive Radioimmunotherapy Radioisotopes Radiolabeled Radiology Specialty Rate Reagent Recommendation Recording of previous events Records Recovery Recruitment Activity Registered nurse Registries Regulation Reporting Reproducibility Reproduction spores Research Research Activity Research Design Research Ethics Committees Research Infrastructure Research Personnel Research Priority Research Project Grants Research Support Research Training Residual Tumors Resistance Resource Allocation Resources Retinoids Review Committee Rights Risk Role Rural Population Safety Sampling Schedule Schools Science Scientific Evaluation Scientist Score Screening procedure Selective Estrogen Receptor Modulators Seminal Senior Scientist Serum Services Shock Signal Pathway Signal Transduction Site Slide Societies Solid Source Southwest Oncology Group Specificity Specimen Speed Staging Strategic Planning Streptavidin Structure Study Section Study Subject Suggestion Supervision Support Groups Surgeon Surgical Oncologist Surgical Oncology Surgical Pathology Surrogate Endpoint Surrogate Markers Survivors Susan G Komen Breast Cancer Foundation System T-Lymphocyte TAG-72 Antigen TNF receptor-associated factor 4 TNFRSF5 gene TP53 gene TRAF4 gene Tamoxifen Techniques Technology Teleconferences Terminology Testing Text Therapeutic Therapeutic Agents Therapeutic Intervention Time TimeLine Tissue Banks Tissue Procurements Tissue Sample Tissues Title Today Toxic effect Toxin Training Training Programs Transactivation Transfection Transgenic Organisms Translational Research Translations Trauma Treatment Protocols Trust Tumor Immunity Tumorigenicity Tyrosine Kinase Inhibitor Ultrasonography Underserved Population United States United States Food and Drug Administration United States National Institutes of Health Universities University Hospitals University of Alabama at Birmingham Cancer Center Update Vaccine Therapy Vaccines Vascular Endothelial Growth Factors Virginia Visit Week Woman Women&apos s Group Women&apos s Health Work Writing abstracting angiogenesis antibody conjugate anticancer research base bevacizumab breast cancer diagnosis breast surgery cancer care cancer diagnosis cancer prevention cancer research center director cancer therapy carcinogenesis career caucasian American chemotherapy college community organizations computer network conditionally replicative adenovirus cooperative study cost effective data acquisition data management day death receptor-4 design desire dosimetry driving force ductal breast carcinoma experience feeding fight against fighting follow-up gastrointestinal gene therapy hormone therapy human TNFRSF10A protein human subject immune function immunogenicity immunopathology improved injured innovation interest intravenous administration investigator training malignant breast neoplasm medical schools medically underserved population member men minority health minority subjects mortality mouse model mullerian-inhibiting hormone multidisciplinary mutant neoplastic cell novel novel therapeutics oncology organizational structure outcome forecast outreach program patient safety peer pilot trial post-doctoral training pre-clinical preclinical study prenatal professor prognostic programs promoter protein expression protocol development psychologic quality assurance racial and ethnic radiotracer receptor research clinical testing research study resistance mechanism response restoration smoothened signaling pathway socioeconomics statistics success survivin symposium therapeutic target time interval tissue resource tool translational study tumor tumor growth tumor progression vector vector vaccine volunteer

项目摘要

The Administrative/Clinical Trials Core (Core A) is responsible for the administrative support of all DAB Breast SPORE Projects, Cores and Programs, including planning and monitoring of scientific activities, providing scientific direction, ensuring a translational research emphasis, and integrating the Projects, Cores and Programs, including collaborations with other Breast SPORES.The Administrative/Clinical Trials Core provides fiscal oversight including 1) employment of key personnel to ensure cost effective and efficient use of resources and 2) utilization of SPORE flexibility to reallocate funds depending on the degree to which the individual Projects and Cores of the UAB Breast SPORE are successful in meeting their performance benchmarks, which allows the Administrative/Clinical Trials Core to take advantage of new scientific opportunities as well as to remedy deficiencies. The Administrative/Clinical Trials Core provides a vital link between investigators and the UAB Breast SPORE internal and external advisors, as well as NCI program staff, and assumes responsibility for the preparation of all required reports and assurances. An important component of the Administrative/Clinical Trials Core is its oversight of UAB Breast SPORE human clinical trials, which provides for enhanced interactions between the UAB Breast SPORE and the UAB Comprehensive Cancer Center (UABCCC). In regards to the conduct of UAB Breast SPORE human clinical trials, the goals of the Administrative/Clinical Trials Core are to: 1) provide optimal support for human clinical trials; 2) provide patients access to interventions/therapies developed by UAB Breast SPORE investigators; 3) enhance interactions between UAB Breast SPORE basic and clinical investigators; and 4) provide for enhancement and coordination of the resources available through the UABCCC Clinical Trials Shared Facility for utilization by UAB Breast SPORE investigators. Currently, the Breast SPORE has 12 clinical trials generated by SPORE projects, developmental projects or inter-SPORE collaborations. The Administrative/Clinical Trials Core also manages a registered UAB Breast SPORE website and contributes to the Cancer Center Magazine, which serves the UAB community and the friends and supporters of the UABCCC. The Administrative/Clinical Trials Core supports all of the SPORE Projects with planning, monitoring and the achievement of the scientific objectives of each SPORE Project/Core facility.

行政/临床试验核心（核心 A）负责所有 DAB 的行政支持乳房孢子项目、核心和计划，包括科学活动的规划和监测，提供科学方向，确保转化研究重点，并整合项目，核心和计划，包括与其他乳房 SPORES 的合作。行政/临床试验核心提供财政监督，包括 1) 雇用关键人员以确保成本效益和有效利用资源，2) 利用 SPORE 根据程度灵活地重新分配资金 UAB 乳房孢子的各个项目和核心成功地满足了他们的要求性能基准，这使得管理/临床试验核心能够利用新的科学机会以及弥补缺陷。行政/临床试验核心提供了研究人员与 UAB Breast SPORE 内部和外部顾问以及 NCI 之间的重要联系计划工作人员，并负责准备所有必需的报告和保证。行政/临床试验核心的一个重要组成部分是对 UAB Breast SPORE 的监督人体临床试验，增强了 UAB 乳房孢子和 UAB 综合癌症中心 (UABCCC)。关于UAB Breast SPORE human的行为临床试验中，管理/临床试验核心的目标是：1) 提供最佳支持人体临床试验； 2) 为患者提供 UAB Breast 开发的干预措施/疗法孢子调查员； 3）增强UAB乳腺SPORE基础与临床之间的相互作用调查员； 4) 通过以下方式加强和协调可用资源： UABCCC 临床试验共享设施，供 UAB 乳腺 SPORE 研究人员使用。目前，乳房 SPORE 拥有 12 项由 SPORE 项目、开发项目或 SPORE 间产生的临床试验合作。行政/临床试验核心还管理注册的 UAB Breast SPORE 网站和为癌症中心杂志撰稿，该杂志为 UAB 社区以及朋友和 UABCCC的支持者。行政/临床试验核心支持所有 SPORE 项目的规划、监控和每个 SPORE 项目/核心设施的科学目标的实现。